Response of omalizumab in normocomplementemic urticarial vasculitis

J Allergy Clin Immunol Pract. 2020 Jun;8(6):2114-2117.e2. doi: 10.1016/j.jaip.2020.02.024. Epub 2020 Mar 5.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Omalizumab / therapeutic use
  • Urticaria* / drug therapy
  • Vasculitis, Leukocytoclastic, Cutaneous*

Substances

  • Omalizumab

Associated data

  • ChiCTR/ChiCTR1900024869